GenoMethods covers biotechnology through the editorial framework Method → Medicine → Market. The team structure reflects the different kinds of expertise needed to explain biotechnology from technical method through clinical development and commercial context.
Browse all GenoMethods author profiles: All Authors.
Adrian Cole
Founder & Editor-in-Chief, Bioengineering & Methods
- Coverage
- Bioengineering, genome and cell engineering, synthetic biology, genomics, sequencing technologies, computational biology, AI-assisted biological research, research instrumentation and emerging experimental platforms.
- Editorial focus
- Experimental design, controls, benchmarking, reproducibility, methodological limitations and the distinction between an early prototype and a reliable method. His coverage emphasizes how a technology was evaluated, what comparison is meaningful and what additional evidence would strengthen confidence in the method.
- Topics
- Bioengineering; Genome Editing; Computational Biology
- Adrian.Cole@genomethods.org
Elena MacLeod
Clinical Biotechnology Editor
Elena MacLeod covers CAR-T, engineered cell therapies, gene therapy, cancer immunology, clinical trials, regulatory developments, early-stage oncology, safety, efficacy and biomarkers. Her coverage focuses on what clinical evidence can reasonably establish at each stage of development.
- Editorial focus
- Patient populations, dose cohorts, endpoints, adverse events, durability, follow-up, attrition, manufacturing and the distinction between biological activity and established clinical benefit. Particular attention is given to limitations that materially affect how trial results should be interpreted.
- Topics
- CAR T-cell Therapy; Clinical Trials; Gene Therapy
- Elena.MacLeod@genomethods.org
Vivian Lin
Biotech Markets & Transactions Editor
Vivian Lin covers biotechnology licensing, M&A, financing, pipelines, strategic partnerships, cross-border transactions, private placements, reverse mergers and restructurings. Her reporting connects financial events to the biotechnology assets and development programs behind them.
- Editorial focus
- Transaction economics, including upfront payments, milestones, royalties, territorial rights and development responsibilities, connected to the underlying scientific and clinical evidence. Headline transaction values are considered in the context of the economic terms actually disclosed.
- Topics
- Biotechnology; Mergers and Acquisitions; Venture Capital
- Vivian.Lin@genomethods.org
Editorial Leadership
Newsroom Contacts
General editorial questions, source suggestions and story ideas: editorial@genomethods.org
Suspected factual errors in published material: corrections@genomethods.org
Related Pages
1 Broadway
Cambridge, MA 02142
United States